Time to Buy Orphazyme (ORPH) Stock?

Orphazyme (ORPH) is losing 40% from $1.26 to $0.76 at the time of writing. Only one bad news needed to crash the stock in hours. Orphazyme’s board of directors has decided to file an in-court restructuring of the company. Consequently, it will reduce 50% of the company’s current worldwide workforce.Orphazyme Clinical Trial Hits Full Enrollment | The ALS Association

  • The top management is having a quest of reducing the company’s operation partially, selling some assets to support cash flow, or injecting new capital.
  • To assist cost reduction the company has already ceased its operations in Germany, the UK, and the U.S.
  • As a result of serious depression, Orphazyme has started negotiations under Danish Law.
  • From this day on, the company will be running only in Denmark unless new investors arrive as saviors.

If Orphazyme stock keeps plunging to the $0.10 mark Nasdaq may remove its shares from its listing. OTC market will welcome it for sure. Closing its operations in the USA can pave a way to stop its shares from being sold overseas smoothly.A Closer Look at Historical Bear Markets